Peptide Comparison
ARA-290 (Cibinetide)vsThymosin Beta-4
A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
ARA-290 (Cibinetide)
0.16 mg–0.8 mg mg
Thymosin Beta-4
2–5 mg
Frequency
ARA-290 (Cibinetide)
Once daily
Thymosin Beta-4
Twice weekly
Administration
ARA-290 (Cibinetide)
Subcutaneous injection
Thymosin Beta-4
Subcutaneous injection
Cycle Length
ARA-290 (Cibinetide)
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset Speed
ARA-290 (Cibinetide)
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
ARA-290 (Cibinetide)
Moderate human trials (Phase 1-2)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Nerve Regeneration
Pain Management
Tissue Protection
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
ARA-290 (Cibinetide)
Molecular Formula
C51H84N16O21
Molecular Weight
1257.31 g/mol
Half-Life
Approximately 1-2 hours in circulation, but cellular effects last much longer
Bioavailability
Subcutaneous: ~100% (complete absorption); Intravenous: Immediate
CAS Number
1208243-50-8
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Applications
Best
suited for
ARA-290 (Cibinetide)
Treating small fiber neuropathy
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing neuropathic pain from diabetes or sarcoidosis
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting nerve regeneration after injury
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic inflammation
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
ARA-290 (Cibinetide)
Common
- Injection Site Reactions
- Headache
- Dizziness
Uncommon
- Elevated Blood Pressure
- Fatigue
Serious
- Blood Clot Formation
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
ARA-290 (Cibinetide)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Not FDA approved
Safety Overview
ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.
Contraindications
- xPolycythemia vera or erythrocytosis
- xUncontrolled hypertension
- xPregnancy or breastfeeding
- xKnown hypersensitivity to peptides
- xConcurrent use with certain cancer medications
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose ARA-290 (Cibinetide) if...
- Treating small fiber neuropathy
- Managing neuropathic pain from diabetes or sarcoidosis
- Supporting nerve regeneration after injury
- Reducing chronic inflammation
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation